<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145546</url>
  </required_header>
  <id_info>
    <org_study_id>XHEC-C-2013-013-2</org_study_id>
    <nct_id>NCT02145546</nct_id>
  </id_info>
  <brief_title>Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation</brief_title>
  <acronym>ADA-PAF</acronym>
  <official_title>Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic (Shanghai) Management Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing CTSmed Co. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current evidences indicate that ~30% patients with sick sinus syndrome(SSS) would develop
      persistent atrial fibrillation (AF) after a long term pacing therapy. However, the accurate
      influence of antiarrhythmic drugs on the AF is still not well defined. The purpose of the
      study is to assess the therapeutic effects of various antiarrhythmic drugs (Amiodarone,
      Sotalol and Propafenone) on the long term management of AF in SSS patients with AF, including
      the reduced AF burden (duration and episodes) and persistent AF free survival rate. All
      patients will be followed up for 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average AF burden in minutes per day</measure>
    <time_frame>monthly up to 12 months</time_frame>
    <description>Long term usages of test drug reduce AF burden, including the number and accumulated total time of AF per day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent AF free survival rate</measure>
    <time_frame>monthly up to12 months</time_frame>
    <description>Long term usages of test drugs reduce the occurence of the persistent AF ( the persistent AF survival rate)。</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>0months, 6months and 12 months</time_frame>
    <description>LVEF(Simpson), LV volume, diastolic function (E/A ), tricuspid regurgitation, Left atrial size and volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 health survey</measure>
    <time_frame>0 months, 6 months and 12 months</time_frame>
    <description>SF-36 health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comorbidity and mortality</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The rate of stroke, infarction, heart failure, rehospitalization and cardiovascular and total mortality rate.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will take Amiodarone orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotalol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take sotalol orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propafenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take propafenone orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will take no antiarrhythmic drugs except β-blocker</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.</description>
    <arm_group_label>Amiodarone</arm_group_label>
    <other_name>cordarone</other_name>
    <other_name>pacerone</other_name>
    <other_name>aratac</other_name>
    <other_name>arycor</other_name>
    <other_name>atlansil</other_name>
    <other_name>tachyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propafenone</intervention_name>
    <description>150mg per 8 hours, 3 times per day</description>
    <arm_group_label>Propafenone</arm_group_label>
    <other_name>rythmol SR</other_name>
    <other_name>rytmonorm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotalol</intervention_name>
    <description>80mg twice per day.</description>
    <arm_group_label>Sotalol</arm_group_label>
    <other_name>betapace</other_name>
    <other_name>betapace AF</other_name>
    <other_name>sotalex</other_name>
    <other_name>sotacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years old

          -  sick sinus syndrome with pacemaker Class I or Class IIa indication

          -  has a pacemaker which can provide the daily AF burden monitor record for at least 28
             days

          -  has at AF record in the past 6 months, the valid AF record includes any of

               1. at least one 30 seconds AF holter record

               2. at least one 15 seconds 12-ECG record

               3. at least 5 minutes long AF episodes record from pacemakers

          -  able and willing to give informed consent

        Exclusion Criteria:

          -  will have cardiac surgery in the next 6 month or in the waiting list of heart
             transplantation

          -  NYHA Class III or IV

          -  LVEF &lt;50%

          -  Reversible AF, such as AF caused by hyperthyroidism or severe postoperative atrial
             fibrillation

          -  Persistence AF

          -  Expected life expectancy less than 1 year

          -  Planned to be pregnant or be in the feeding period in the next year

          -  Non-stable, decompensated heart failure

          -  Allergy to Amiodarone, Propafenone or Sotalol

          -  Cancer

          -  Clear liver damage ( ALT and/or AST &gt; 2*normal limit)

          -  Patients with cardiogenic shock history

          -  Be in the treatment of Amiodarone for more than 3 months or less than 3 months with
             Amiodarone wash out period less than 30 days

          -  Coronary artery disease (CHD), cardiomyopathy, severe valvular heart disease, severe
             obstructive pulmonary disease (COPD), long QT syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Gang Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiaotong University School of Medicne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Gang Li, MD</last_name>
    <phone>13761318166</phone>
    <email>drliyigang@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Liu, MD</last_name>
    <phone>13816037607</phone>
    <email>liuboxinhua@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicne</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yi-Gang Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>OSTRANDER LD Jr, BRANDT RL, KJELSBERG MO, EPSTEIN FH. ELECTROCARDIOGRAPHIC FINDINGS AMONG THE ADULT POPULATION OF A TOTAL NATURAL COMMUNITY, TECUMSEH, MICHIGAN. Circulation. 1965 Jun;31:888-98.</citation>
    <PMID>14297523</PMID>
  </reference>
  <reference>
    <citation>Zhou ZQ, Hu DY, Chen J, Zhang RH, Li KB, Zhao XL. [An epidemiological survey of atrial fibrillation in China]. Zhonghua Nei Ke Za Zhi. 2004 Jul;43(7):491-4. Chinese.</citation>
    <PMID>15312400</PMID>
  </reference>
  <reference>
    <citation>Siu CW, Jim MH, Zhang X, Chan YH, Pong V, Kwok J, Kung AW, Lau CP, Tse HF. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol. 2009 Feb 15;103(4):540-3. doi: 10.1016/j.amjcard.2008.10.019. Epub 2008 Dec 25.</citation>
    <PMID>19195517</PMID>
  </reference>
  <reference>
    <citation>Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005 May 5;352(18):1861-72.</citation>
    <PMID>15872201</PMID>
  </reference>
  <reference>
    <citation>Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000 Mar 30;342(13):913-20.</citation>
    <PMID>10738049</PMID>
  </reference>
  <reference>
    <citation>Pritchett EL, Page RL, Carlson M, Undesser K, Fava G; Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003 Oct 15;92(8):941-6.</citation>
    <PMID>14556870</PMID>
  </reference>
  <reference>
    <citation>Israel CW. Analysis of mode switching algorithms in dual chamber pacemakers. Pacing Clin Electrophysiol. 2002 Mar;25(3):380-93. Review.</citation>
    <PMID>11990674</PMID>
  </reference>
  <reference>
    <citation>Passman RS, Weinberg KM, Freher M, Denes P, Schaechter A, Goldberger JJ, Kadish AH. Accuracy of mode switch algorithms for detection of atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2004 Jul;15(7):773-7.</citation>
    <PMID>15250860</PMID>
  </reference>
  <reference>
    <citation>Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH, Brandes A, Crystal E, Costantini O, Sandhu RK, Parkash R, Connolly SJ, Hohnloser SH, Healey JS; ASSERT Steering Committee and Investigators. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm. 2012 Aug;9(8):1241-6. doi: 10.1016/j.hrthm.2012.03.017. Epub 2012 Mar 20.</citation>
    <PMID>22440154</PMID>
  </reference>
  <reference>
    <citation>Nowak B, McMeekin J, Knops M, Wille B, Schröder E, Moro C, Oelher M, Castellanos E, Coutu B, Petersen B, Pfeil W, Kreuzer J; Stored EGM in PulsarMax II and Discovery II Study Group. Validation of dual-chamber pacemaker diagnostic data using dual-channel stored electrograms. Pacing Clin Electrophysiol. 2005 Jul;28(7):620-9.</citation>
    <PMID>16008796</PMID>
  </reference>
  <reference>
    <citation>Charles D. Swerdlow, Jeffrey M. Gillberg, Paul Khairy, Textbook, Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy, Chapter 3, Sensing and Detection, page 146.</citation>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Yi-Gang Li</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Pacing dependent</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Amiodarone</keyword>
  <keyword>Propafenone</keyword>
  <keyword>Sotalol</keyword>
  <keyword>AF burden</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Sotalol</mesh_term>
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

